((自动化翻译由路透提供，请见免责声明 ))
11月5日 - ** 生物制药公司Apellis Pharmaceuticals 股价下跌8.9%至26.02美元
** APLS 以近三个月低点开盘
** 该公司公布的第三季度亏损超出预期
** 第三季度亏损46美分/每小时，预计亏损30美分/每小时 - LSEG
** 公司第三季度实现营业收入 1.968 亿美元，预计为 2.0035 亿美元 - LSEG
** APLS的SYFOVRE注射液可治疗一种名为地理萎缩 的黄斑变性疾病 (GA)，该产品于9月份获得了人用医药产品委员会的否定意见$(CHMP)$
** 由于毛额对净额的调整增加，SYFOVRE 的净销售价格与前几个季度相比有所下降 - APLS
** 公司还预计英国、瑞士、加拿大和澳大利亚将于 2025 年初对 SYFORVE 做出监管决定
** 21 位分析师中有 15 位将 APLS 评为 "买入 "或更高，6 位 "持有"，PT 中值为 68 美元 - LSEG
** 截至上次收盘，该股今年累计下跌约 52
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.